Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AlloBMT should be option for older adults with hematologic malignancies

Key clinical point: Allogeneic bone marrow transplant with posttransplant cyclophosphamide is safe and feasible in older adults.

Major finding: Overall survival was 64% at 1 year and 43% at 3 years.

Study details: A review of 108 consecutive cases.

Disclosures: Dr. Imus reported having no financial disclosures.

Citation:

Imus P et al. TCT 2019, Abstract 42.